Riik: Austraalia
keel: inglise
Allikas: Department of Health (Therapeutic Goods Administration)
Paclitaxel
Bristol-Myers Squibb Australia Pty Ltd
Medicine Registered
TAXOL ® _Paclitaxel_ CONSUMER MEDICINE INFORMATION WHAT IS IN THIS LEAFLET This leaflet answers some common questions about Taxol. It does not take the place of talking to your doctor or pharmacist. All medicines have risks and benefits. Your doctor has weighed the risks of you taking Taxol against the benefits that are expected. This leaflet does not contain everything about Taxol. Your doctor has been provided with full information and can answer any questions you may have. Follow your doctor's advice even if it differs from what is in this leaflet. Please read this leaflet carefully and keep it in a safe place so you may refer to it later. WHAT TAXOL IS USED FOR Taxol is used to treat cancer of the ovary, the breast, and non small cell cancer of the lung. Taxol may be used alone or in combination with other anticancer agents. Taxol is not recommended for use in children as its safety and effectiveness in patients under 18 years of age has not been established. Ask your doctor if you have any questions about why Taxol was prescribed for you. _HOW TAXOL WORKS_ Taxol belongs to a class of anticancer agents known as taxanes. These agents prevent the division of cells, particularly cancer cells. The use of Taxol to treat your cancer can lead to side-effects, which are discussed below. _HOW TAXOL IS USED_ Taxol will be administered as an infusion in a hospital clinic. Taxol may be used alone or with other anticancer medicines. The dose is worked out based on your body weight and height, and so may be different from the dose chosen for other people. Taxol is administered as an intravenous infusion over a 3 hour period. Administration will occur at 3 week intervals. The administration of Taxol requires all patients to be given premedication prior to Taxol. The premedication consists of three other drugs which work by reducing the likelihood of an allergic reaction occurring when you receive your Taxol. They are given as tablets 12 and 6 hours before the Taxol is given and two injections into the vein Lugege kogu dokumenti
Taxol V5 26 August 2013 - 1 - PRODUCT INFORMATION TAXOL NAME OF THE MEDICINE TAXOL contains paclitaxel, a natural product with antitumour activity. TAXOL is the first of a new class of anticancer agents known as taxanes. The CAS number for paclitaxel is 33069-62-4 (USAN). Paclitaxel has the following structural formula: Molecular Formula: C 47 H 51 NO 14 Molecular Weight: 853.929 DESCRIPTION Paclitaxel is a white to off-white crystalline powder that is highly lipophilic and insoluble in water. PHARMACOLOGY PHARMACOKINETICS The pharmacokinetics of paclitaxel have been evaluated over a wide range of doses, up to 300 mg/m 2 , and infusion schedules, ranging from 3 to 24 hours. Following intravenous administration, paclitaxel exhibits a biphasic decline in plasma concentrations. The initial rapid decline represents distribution to the peripheral compartment and elimination; the later phase is due, in part, to a relatively slow efflux of paclitaxel from the peripheral compartment. Maximum plasma concentrations are related to dose. In patients treated with doses of 135 and 175 mg/m 2 given as 3 and 24 hour infusions, mean terminal half-life has ranged from 3.0 to 52.7 hours, and total body clearance has ranged from 11.6 to 24.0 L/h/m 2 . Taxol V5 26 August 2013 - 2 - Mean steady state volume of distribution following single dose infusion of 135 and 175 mg/m 2 has ranged from 198 to 688 L/m 2 , indicating extensive extravascular distribution and/or tissue binding. The volume of distribution is reduced in female subjects. Following 3 hour infusions of 175 mg/m 2 , mean terminal half-life was estimated to be 9.9 hours; mean total body cle Lugege kogu dokumenti